Atlas Trials

Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer

Clinical trial NCT05132504 · RECRUITING

Trial details

NCT number
NCT05132504
Sponsor
Baylor College of Medicine
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Pancreatic Ductal Adenocarcinoma
Start date
2022-08-31
Primary completion
2027-05-21
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.